In this session, leading experts on graft-versus-host disease (GVHD), a common complication after a bone marrow/stem cell transplant, respond to questions about who is at risk of developing GVHD, symptoms of GVHD, and how to manage both the physical and emotional problems associated with GVHD and its treatment.

This session features leading experts in CAR T-cell therapy for lymphoma and multiple myeloma, and a social worker who helps CAR T patients manage psychosocial and financial challenges during and after treatment. They discuss current CAR T therapies available for myeloma and lymphoma patients, side effects and outcomes after CAR T-cell therapy, and new CAR T products on the horizon.

Acute myeloid leukemia (AML) is a rare disease that is seen most often in older adults, although it can occur in younger people as well. This webinar discusses the symptoms of AML, how it is diagnosed, risk factors for developing AML, and current treatment options.

CAR T-cell therapy is a type of specialized immunotherapy that uses the patient's own modified T-cells to fight cancer. It is approved to treat certain blood cancers like lymphoma, leukemia, and multiple myeloma.

A transplant using the patient's own stem cells (an autologous stem cell transplant) or CAR T-cell therapy are treatment options for patients with certain types of lymphoma.

The COVID 19 pandemic has become an endemic disease that requires ongoing vigilance from stem cell transplant recipients. This presentation reviews current guidelines for when to test for COVID and the varieties of treatments that have become available since the onset of the virus.

Acute myeloid leukemia is a fast-moving cancer that can be fatal in weeks or months without treatment. This presentation reviews the causes, symptoms, and treatments for AML and recent progress in cure rates or prolonged remission for an increasing number of patients.

Genital graft-versus-host-disease can be a lifelong risk for female stem cell or bone marrow transplant recipients. The presentation reviews the symptoms of vaginal and vulvar GVHD and discusses treatments that can restore women to full sexual health and functioning. Many thanks to Kadmon, a Sanofi company, and Syndax Pharmaceuticals, whose support, in part, made this webinar possible.